GA
BSX icon

Geneva Advisors’s Boston Scientific BSX Stock Holding History

Geneva Advisors’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-28,294
Closed -$661K – 759
2016
Q2 		$661K Buy
+28,294
New +$612K 0.01% 387

Other funds holding BSX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Geneva Advisors's BSX Position: Q3 2016 in Review

Geneva Advisors sold out of Boston Scientific (BSX) in Q3 2016, closing a stake of 28,294 shares — an estimated $661K sold.

Geneva Advisors first reported a position in BSX in Q2 2016 and held it in 1 quarter. The position peaked at $661K in Q2 2016. 565 funds tracked by Wall St. Rank hold BSX as of Q3 2016.

  • Geneva Advisors reported no remaining Boston Scientific position as of Q3 2016 after selling out during the quarter.
  • Geneva Advisors sold 28,294 Boston Scientific shares in Q3 2016, an estimated $661K.
  • Geneva Advisors first reported a position in Boston Scientific in Q2 2016 and held it in 1 quarter.
  • Geneva Advisors's Boston Scientific position peaked at $661K in Q2 2016.
  • 565 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2016.

Based on Geneva Advisors's 13F filing for Q3 2016, filed 9 Nov 2016.